How much revenue does Joincare Pharmaceutical Group Industry make?

Joincare Pharmaceutical Group Industry reported 15.22 billion CNY in revenue for fiscal year 2025, down 2.6% from 15.62 billion CNY in fiscal year 2024. In Q1 2026 revenue was 3.72 billion CNY.

Where does Joincare Pharmaceutical Group Industry make most of its revenue?

China: 82% of revenue by region in fiscal year 2025, followed by Overseas (18%).

What companies are similar to Joincare Pharmaceutical Group Industry?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Beijing Tiantan Biological Products Co., Ltd. (600161.SS), Hualan Biological Engineering Inc. (002007.SZ), Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ), ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ).

Joincare Pharmaceutical Group Industry Co.,Ltd. (600380.SS) Stock

About Joincare Pharmaceutical Group Industry Co.,Ltd.

Joincare Pharmaceutical Group Industry Co.,Ltd. engages in the research, development, production, and sale of pharmaceuticals and health care products in China and internationally. The company offers chemical pharmaceuticals for respiratory, gastroenterology, assisted reproduction, psychiatry, and anti-infection; chemical APIs and intermediates for drugs for humans and veterinary drugs; and tradit...

At a glance

Joincare Pharmaceutical Group Industry reported revenue of 15.22 billion CNY for fiscal year 2025, down 2.6% from fiscal year 2024, and net income of 1.34 billion CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 3.72 billion CNY, down 9.0% from a year before. China was its largest region in fiscal year 2025, with 82% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.